Immunovant, Inc. (IMVT)
Immunovant develops IMVT-1402, an experimental antibody treatment for autoimmune diseases driven by harmful IgG antibodies. It last closed at $33.21 on Nov 17, down 0.21% on the day. IMVT reports earnings on Fri, Feb 5, 2027. The average 12-month price target from 2 analysts is $40.00 (+20.4% from the last close), with a high of $47.00 and a low of $33.00. Over the past 90 days StreetAlpha recorded 2 whale options trades in IMVT, 50% of them bullish and 50% bearish.
Key Stats
Last 12 monthsNot reported for this period.
From IMVT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 2 analysts who set a price target on IMVT in the past 90 days. The average target is $40.00, with a high of $47.00 and a low of $33.00, compared with the last close of $33.21.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 10 | Truist Securities | Target raised | Hold | $30 → $33 |
| Nov 10 | Wells Fargo | Maintained | Buy | $47 |
| Aug 4 | JP Morgan | Maintained | Buy | $50 |
| Jun 30 | Citigroup | Maintained | Buy | $61 |
| May 26 | Guggenheim | Maintained | Buy | $62 |
Technical Analysis
The stock is 6% above its 20 day and 2% above its 50 day average. It is 2% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 54). The nearest support is the Pivot at $33.16, and the nearest resistance the Pivot R1 at $33.87.
| RSI (14) | 54.35 | Middle of its range | Neutral |
| MACD | 0.79 | Above its signal line | Bullish |
| Stochastic | 57.5 | Middle of its range | Neutral |
| ADX (14) | 30.6 | Trending up | |
| Williams %R | -46.3 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 54.4 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +14.4% | Change over 10 sessions | Bullish |
| ATR (14) | $1.56 | Typical daily range, 4.7% of price |
| RSI (14) | 50.03 | Middle of its range | Neutral |
| MACD | -0.36 | Below its signal line | Bearish |
| Stochastic | 33.2 | Middle of its range | Neutral |
| ADX (14) | 28.2 | Trending up | |
| Williams %R | -63.8 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -42.8 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −11.1% | Change over 10 sessions | Bearish |
| ATR (14) | $3.38 | Typical daily range, 10.2% of price |
What happened before
See how IMVT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How IMVT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.
Whale Options Flow
90DNo whale options trades in IMVT in the last 90 days.
IMVT Institutional Ownership
Full report →- ●116 buying vs 102 selling
- ▼Held by funds -0.7 pts
- ▲Funds holding +7
- ▼Superinvestors: 1 added, 3 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 233 | 226 | +3.1% |
| In funds' top 10 | 8 | 7 | +14.3% |
| Held by funds | 52.7% | 53.4% | −0.7 pts |
| New / increased | 36 / 80 | 37 / 74 | +4.5% |
| Reduced / sold out | 73 / 29 | 79 / 24 | −1.0% |
| Put/call ratio | 0.00 | 0.00 | −70.7% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IMVT is in one of them and how their past IMVT trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered IMVT in an article yet. Here's the latest on the wider market.
About Immunovant
Immunovant is a drug developer focused on autoimmune diseases, based in Durham, North Carolina. Its main product candidate, IMVT-1402, is an antibody designed to block the FcRn protein and lower levels of harmful IgG antibodies. The company is testing the candidate in conditions such as Graves' disease, myasthenia gravis and rheumatoid arthritis. The treatment is being developed for injection that patients can give themselves. Its intended patients are people living with autoimmune diseases driven by IgG antibodies.
- Headquarters
- Durham, NC


